Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CAPTURE-CTC

Financiado

Cerrado

A Streptavidin Microarray Platform for Capturing of Circulating Tumor Cells from...

A Streptavidin Microarray Platform for Capturing of Circulating Tumor Cells from the Blood of Cancer Patients The main cause of death in cancer patients is not the primary tumor but rather metastasis, which is initiated by the spread of circulating tumor cells (CTCs) in the blood. Therefore, CTCs will become a valuable diagnostic tool, on... ver más

30/11/2016

UKE

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-11-30

ERC-PoC-2014: ERC Proof of Concept Grant Scope:Objectives

I+D

Cerrada hace 10 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UKE

149.75K€ | Lider

JOSE REVERTE NAVARRO, SL

308.55K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

pureCTC A LAB ON A CHIP DEVICE FOR PURE CIRCULATING TUMOR CELL ISOLA... 173K€ Cerrado

BIO2011-30535-C04-03 SEPARACION ACUSTICA DE CELULAS TUMORALES EN SANGRE CON CHIPS... 80K€ Cerrado

uQuantEV Microfluidic EV Quantification for Point-of-Care CRC diagnos... 165K€ Cerrado

IMPED INTEGRATED MICROFLUIDIC PLATFORM FOR PROTEOMIC AND GENETIC E... 225K€ Cerrado

CanDo A CANcer Development mOnitor 5M€ Cerrado

EUIN2013-51200 NUEVAS PLATAFORMAS MICROFLUIDICAS BASADAS EN MECANICA CELULA... 20K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2015-05-28
Fecha Fin: 2016-11-30

Líder del proyecto

UNIVERSITAETSKLINIKUM HAMBURGEPPENDORF No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The main cause of death in cancer patients is not the primary tumor but rather metastasis, which is initiated by the spread of circulating tumor cells (CTCs) in the blood. Therefore, CTCs will become a valuable diagnostic tool, once a reliable, cost-effective method is established. Research in the ongoing ERC Advanced Investigator Grant DISSECT (PI: Klaus Pantel) has revealed clear limitations of existing platforms for the detection of CTCs. The enrichment and identification of CTCs out of a blood sample is still a major challenge, mainly because the ratio between CTCs and blood cells is approximately 1:109. The proposed CAPTURE-CTC project is based on this knowledge and aimed to develop and validate a novel improved platform for CTC detection: Pumping a suspension of blood cells through a microfluidic chip, only labeled CTCs get immobilized on a micro-pattern due to strong biotin-streptavidin interaction. Single cell analysis can be performed after the cells are quantified, optically localized and extracted from the pattern with a micro-capillary. This platform will be validated on cancer patients. The detection of CTCs is a very active field, targeted by several SMEs with approaches in different stages of development and/or clinical application. However, the only FDA-cleared assay for CTC detection is the CellSearch CTC Test which will be the benchmark in regard to performance, validity of results and cost per test. The CellSearch system has technical limitations (e.g., EpCAM-negative CTCs are not captured and it is a closed system that allows no easy access to the captured CTCs for subsequent molecular characterization analyses). Our proposed CAPTURE-CTC system will constitute a novel platform that will overcome these important limitations and establish an easy-to-use blood test allows further downstream analyses of CTCs as a liquid biopsy relevant to personalized cancer medicine.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores